BioLineRx Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2009
Net Income	-60.61	-24.95	-27.05	-30.02	-25.45	-22.96	-24.35	-15.84	-14.4	-11.08	Upgrade
Depreciation & Amortization	1.38	0.65	0.7	0.93	0.94	0.55	0.48	0.48	0.44	0.27	Upgrade
Share-Based Compensation	2.32	2.25	1.5	1.27	1.76	2.53	1.51	1.08	1.15	1.06	Upgrade
Other Operating Activities	34.3	-4.19	1.28	4.61	0.08	-4.3	1.82	-0.23	-1.36	-6	Upgrade
Operating Cash Flow	-22.61	-26.24	-23.57	-23.21	-22.67	-24.19	-20.55	-14.51	-14.17	-15.75	Upgrade
Capital Expenditures	-0.12	-0.13	-0.1	0	-0.07	-0.17	-0.34	-0.05	-2.68	-0.19	Upgrade
Change in Investments	1.74	4.32	-38.13	16.67	5.33	19.77	-11.69	9.35	-12.88	-19.54	Upgrade
Other Investing Activities	-0.18	-0.19	-	-	-0.01	-10.04	-3.9	-0	-0.04	-0.01	Upgrade
Investing Cash Flow	1.44	4.01	-38.22	16.67	5.26	9.56	-15.93	9.3	-15.6	-19.73	Upgrade
Share Issuance / Repurchase	14.12	14.36	50.41	19.25	20.3	3.88	38.77	2.18	29.05	32.64	Upgrade
Debt Issued / Paid	-1.99	6.07	-3.57	-3.36	-1.1	9.22	-0.09	-0.09	0.44	0	Upgrade
Other Financing Activities	2.93	-	10.91	1.97	-	-	-	-	-	-	Upgrade
Financing Cash Flow	15.06	20.44	57.75	17.87	19.19	13.1	38.68	2.09	29.49	32.64	Upgrade
Exchange Rate Effect	-0.22	-0.61	0.21	0.21	0.11	-0.17	0.44	0.05	0.03	-0.27	Upgrade
Net Cash Flow	-6.11	-1.8	-4.05	11.33	1.79	-1.54	2.21	-3.13	-0.28	-2.84	Upgrade
Free Cash Flow	-22.72	-26.37	-23.67	-23.21	-22.73	-24.37	-20.89	-14.57	-16.85	-15.94	Upgrade
Free Cash Flow Margin	-473.42%	-	-	-	-	-	-	-	-	-	Upgrade
Free Cash Flow Per Share	-0.35	-0.51	-0.54	-1.38	-2.33	-3.37	-3.48	-3.89	-4.92	-7.37	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).